Masimo (NASDAQ: MASI) EVP Anand exercises options and sells stock under plan

Rhea-AI Filing Summary

Masimo Corporation executive Sampath Anand, EVP of Ops & Clinical Research, exercised stock options and sold shares of common stock. On January 28, 2026, he exercised 30,000 non-qualified stock options at an exercise price of $37.84 per share, receiving 30,000 shares.

That same day he sold Masimo common stock in three transactions under a Rule 10b5-1 sales plan dated September 12, 2025. He sold 11,924 shares at a weighted average price of $136.56, 6,560 shares at $137.22, and 196 shares at $138.09. Following these transactions, he directly owned 40,909 Masimo shares.

Insider Trade Summary

Net Seller: 18,680 shares ($2,555,570)

Net Sell 5 txns

Insider Sampath Anand

Role EVP, Ops & Clinical Research

Sold 18,680 shs ($2.56M)

Type	Security	Shares	Price	Value
Exercise	Non-Qualified Stock Option (Right to Buy)	30,000	$0.00	--
Exercise	Common Stock	30,000	$37.84	$1.14M
Sale	Common Stock	11,924	$136.56	$1.63M
Sale	Common Stock	6,560	$137.22	$900K
Sale	Common Stock	196	$138.09	$27K

Holdings After Transaction: Non-Qualified Stock Option (Right to Buy) — 0 shares (Direct); Common Stock — 59,589 shares (Direct)

Footnotes (1)

1. The shares covered by this Form 4 were exercised and sold pursuant to a Rule 10b5-1 Sales Plan dated as of September 12, 2025, which is intended to comply with Rule 10b5-1 promulgated under the Securities Exchange Act of 1934, as amended. The price reported in Column 4 represents the weighted average purchase price per share. The actual sale prices ranged from a low of $135.94 per share to a high of $136.94 per share. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. The price reported in Column 4 represents the weighted average purchase price per share. The actual sale prices ranged from a low of $136.95 per share to a high of $137.89 per share. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. The price reported in Column 4 represents the weighted average purchase price per share. The actual sale prices ranged from a low of $138.07 per share to a high of $138.12 per share. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. This option was granted on February 29, 2016 and is exercisable as the option vests. The option vested over a 5 year period, with 20% of the shares subject to the option vesting on each anniversary of the grant date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sampath Anand

(Last) (First) (Middle)

C/O MASIMO CORPORATION

52 DISCOVERY

(Street)

IRVINE CA 92618

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MASIMO CORP [ MASI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Ops & Clinical Research

3. Date of Earliest Transaction (Month/Day/Year)
01/28/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/28/2026		M		30,000	A	$37.84	59,589	D
Common Stock	01/28/2026		S(1)		11,924	D	$136.56(2)	47,665	D
Common Stock	01/28/2026		S(1)		6,560	D	$137.22(3)	41,105	D
Common Stock	01/28/2026		S(1)		196	D	$138.09(4)	40,909	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (Right to Buy)	$37.84	01/28/2026		M			30,000	(5)	03/01/2026	Common Stock	30,000	$0	0	D

Explanation of Responses:

1. The shares covered by this Form 4 were exercised and sold pursuant to a Rule 10b5-1 Sales Plan dated as of September 12, 2025, which is intended to comply with Rule 10b5-1 promulgated under the Securities Exchange Act of 1934, as amended.

2. The price reported in Column 4 represents the weighted average purchase price per share. The actual sale prices ranged from a low of $135.94 per share to a high of $136.94 per share. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

3. The price reported in Column 4 represents the weighted average purchase price per share. The actual sale prices ranged from a low of $136.95 per share to a high of $137.89 per share. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

4. The price reported in Column 4 represents the weighted average purchase price per share. The actual sale prices ranged from a low of $138.07 per share to a high of $138.12 per share. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

5. This option was granted on February 29, 2016 and is exercisable as the option vests. The option vested over a 5 year period, with 20% of the shares subject to the option vesting on each anniversary of the grant date.

Remarks:

	/s/ Micah W. Young, Attorney-In-Fact	01/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Masimo (MASI) EVP Sampath Anand report?

Masimo EVP Sampath Anand reported exercising 30,000 non-qualified stock options at an exercise price of $37.84 per share and selling Masimo common stock in multiple transactions on January 28, 2026. These trades were disclosed in a Form 4 insider filing.

How many Masimo shares does Sampath Anand own after this Form 4 filing?

After the reported transactions, Sampath Anand directly owns 40,909 shares of Masimo common stock. This figure reflects his holdings following the exercise of 30,000 stock options and subsequent open-market sales executed on January 28, 2026, as shown in the Form 4.

Were Sampath Anand’s Masimo stock sales under a Rule 10b5-1 plan?

Yes. The filing states that the shares covered by this Form 4 were exercised and sold under a Rule 10b5-1 sales plan dated September 12, 2025. Such pre-arranged plans are designed to comply with Rule 10b5-1 under the Exchange Act.

At what prices did Masimo EVP Sampath Anand sell his shares?

The reported prices are weighted average sale prices. Shares were sold at $136.56, $137.22, and $138.09 per share. Footnotes explain that actual sale prices occurred within narrow ranges around each average and that detailed trade data is available upon request.

What Masimo stock option grant did Sampath Anand exercise in this Form 4?

He exercised a non-qualified stock option for 30,000 shares of Masimo common stock with an exercise price of $37.84 per share. The option was granted on February 29, 2016 and vested over five years, with 20% vesting on each anniversary.

What role does Sampath Anand hold at Masimo (MASI)?

Sampath Anand is identified as an officer of Masimo Corporation with the title EVP, Ops & Clinical Research. He is not listed as a director or 10% owner in the filing, but reports his beneficial ownership of Masimo common stock as required under Section 16.